RJR-2429
RJR-2429 is a nicotinic acetylcholine receptor (nAChR) antagonist. It is a drug that has been researched for its potential use in the treatment of nicotine addiction. RJR-2429 is a selective antagonist for the α4β2 subtype of the nAChR, which is the subtype most closely associated with nicotine addiction.
Chemistry[edit | edit source]
RJR-2429 is a quinuclidine derivative. Quinuclidine is a nitrogen-containing heterocyclic compound. The structure of RJR-2429 includes a quinuclidine ring, which is linked to a phenyl group via a carbonyl group.
Pharmacology[edit | edit source]
RJR-2429 acts as an antagonist at the α4β2 subtype of the nAChR. This means that it blocks the action of acetylcholine (ACh), a neurotransmitter that normally activates this receptor. By blocking the action of ACh, RJR-2429 can reduce the rewarding effects of nicotine, which may help to reduce nicotine addiction.
Clinical significance[edit | edit source]
RJR-2429 has been studied in preclinical trials for its potential use in the treatment of nicotine addiction. However, as of 2021, it has not been approved for this use by any regulatory authority.
See also[edit | edit source]
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
